S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Fund/Baker Bros Advisors/Q1 2024

Baker Bros Advisors

Periodo: Q1 2024 · Depositato: 2024-05-15
Vedi su SEC EDGAR
AUM
$7.97B
Valore totale del portafoglio
Posizioni
87
Titoli dichiarati
Prima Posizione
INCY
25.9% $2.06B
Var. Trimestrali
+8 / -8
nuovi · usciti
⚠️Informativa sui Depositi 13F

I dati AUM mostrati sono calcolati sommando il valore di mercato dichiarato di tutte le posizioni nei depositi SEC 13F-HR — non rappresentano il patrimonio effettivo gestito dal fondo.

  • Escluse liquidità, obbligazioni, private equity, posizioni corte e azioni estere non soggette all'obbligo di dichiarazione.
  • Per le opzioni PUT e CALL, il Valore dichiarato è il valore nozionale delle azioni sottostanti — non il premio pagato. Ciò sovrastima significativamente il capitale effettivamente a rischio.
  • Il patrimonio reale del fondo è tipicamente superiore e include strategie, strumenti e posizioni che non compaiono mai in un 13F.
  • I depositi 13F riguardano i gestori istituzionali con ≥$100M in titoli 13F. Le posizioni riflettono le partecipazioni a fine trimestre, divulgate entro 45 giorni dalla fine del periodo.

Dati provenienti da SEC EDGAR. Questo tracker è a scopo puramente informativo e non costituisce consulenza finanziaria.

Partecipazioni in Portafoglio

Prime 30 posizioni

⚠️ Performance % calcolata dalla data di deposito ( 2024-05-15) si riferisce al titolo sottostante — non al P&L del derivato.
TickerEmittenteNozionalePortafoglio %Al DepositoOra (Fine Giornata)Dal DepositoAllocazione
INCYIncyte Corporation$2.06B25.86%$56.64$116.86+106.3%
25.9%
ONCBeiGene, Ltd.$1.65B20.73%$159.23$297.65+86.9%
20.7%
ACADACADIA Pharmaceuticals Inc.$792.6M9.94%$18.26$25.97+42.2%
9.9%
MDGLMadrigal Pharmaceuticals, Inc.$526.0M6.60%$255.74$528.10+106.5%
6.6%
RYTMRhythm Pharmaceuticals, Inc.$277.2M3.48%$42.68$114.17+167.5%
3.5%
RVMDRevolution Medicines, Inc.$243.3M3.05%$31.68$189.24+497.4%
3.0%
KYMRKymera Therapeutics, Inc.$241.0M3.02%$39.42$113.51+187.9%
3.0%
ABCLAbCellera Biologics Inc.$124.7M1.56%$4.44$8.11+82.7%
1.6%
BCYCBicycle Therapeutics plc$123.1M1.54%$24.25$4.35-82.1%
1.5%
EWTXEdgewise Therapeutics, Inc.$106.5M1.34%$18.02$39.56+119.5%
1.3%
IMCRImmunocore Holdings plc$98.5M1.24%$62.94$32.50-48.4%
1.2%
KODKodiak Sciences Inc.$91.0M1.14%$4.45$38.54+766.1%
1.1%
ROIVRoivant Sciences Ltd.$78.1M0.98%$10.43$35.13+236.8%
1.0%
REPLReplimune Group, Inc.$78.0M0.98%$7.73$11.58+49.8%
1.0%
DNLIDenali Therapeutics Inc.$76.6M0.96%$20.56$25.83+25.6%
1.0%
TRDAEntrada Therapeutics, Inc.$69.0M0.86%$13.76$7.72-43.9%
0.9%
AKROAkero Therapeutics, Inc.$68.5M0.86%
0.9%
RAREUltragenyx Pharmaceutical Inc.$68.5M0.86%$46.97$33.47-28.7%
0.9%
IMTXImmatics N.V.$67.7M0.85%$11.05$9.95-9.9%
0.8%
CERECerevel Therapeutics Holdings, Inc.$67.6M0.85%
0.8%
ARGXargenx SE$59.5M0.75%$397.33$939.68+136.5%
0.8%
NRIXNurix Therapeutics, Inc.$57.1M0.72%$14.58$23.97+64.4%
0.7%
KNSAKiniksa Pharmaceuticals, Ltd.$55.4M0.70%$19.70$64.53+227.6%
0.7%
BCRXBioCryst Pharmaceuticals, Inc.$51.4M0.65%$5.05$9.84+94.8%
0.7%
AVTEAerovate Therapeutics, Inc.$49.7M0.62%
0.6%
SERASera Prognostics, Inc.$49.5M0.62%$9.37$2.00-78.7%
0.6%
PRLDPrelude Therapeutics Inc.$48.0M0.60%$4.69$4.91+4.7%
0.6%
IDYAIDEAYA Biosciences, Inc.$46.6M0.58%$42.52$37.65-11.4%
0.6%
STOKStoke Therapeutics, Inc.$45.5M0.57%$13.49$32.70+142.4%
0.6%
XENEXenon Pharmaceuticals Inc.$42.8M0.54%$42.14$60.96+44.7%
0.5%

Attività Trimestre su Trimestre

Q1 2024 vs. Q4 2023

Nuove Posizioni (8)

TickerEmittenteNozionale
FATEFate Therapeutics, Inc.$13.3M
NMRANeumora Therapeutics, Inc.$8.7M
DYNDyne Therapeutics, Inc.$8.1M
PRAXPraxis Precision Medicines, Inc.$8.0M
SAGESage Therapeutics, Inc.$7.6M
ALPNAlpine Immune Sciences, Inc.$3.2M
FDMT4D Molecular Therapeutics, Inc.$3.2M
VTVTvTv Therapeutics, Inc.$2.3M

Posizioni Chiuse (8)

TickerEmittenteNozionale
MRTXMirati Therapeutics, Inc.$242.1M
Invitae Corporation$131.2M
GRCLGracell Biotechnologies Inc.$20.9M
DAWNDay One Biopharmaceuticals, Inc.$14.6M
SPRYARS Pharmaceuticals, Inc.$11.0M
Invitae Corporation$6.3M
PRAXPraxis Precision Medicines, Inc.$2.9M
NVTAQInvitae Corporation$1.1M

Aumentate (8)

TickerEmittenteNozionaleVar. AzioniDal Deposito
CELCCelcuity Inc.$25.7M+189.9%
BCYCBicycle Therapeutics plc$90.7M+176.1%-82.1%
XNCRXencor, Inc.$6.9M+122.2%
EWTXEdgewise Therapeutics, Inc.$72.5M+87.6%+119.5%
STOKStoke Therapeutics, Inc.$34.8M+65.9%+142.4%
RVMDRevolution Medicines, Inc.$95.7M+46.6%+497.4%
DNLIDenali Therapeutics Inc.$20.6M+43.1%+25.6%
ABCLAbCellera Biologics Inc.$-6.1M+20.1%+82.7%

Ridotte (7)

TickerEmittenteNozionaleVar. AzioniDal Deposito
CATXXXXXPerspective Therapeutics, Inc.$-2.9M-98.0%
ACHLAchilles Therapeutics plc$-0.4M-42.5%
IMCRImmunocore Holdings plc$-73.7M-39.9%-48.4%
OPTEYOpthea Limited$1.3M-15.9%
SGMTSagimet Biosciences Inc.$-0.4M-5.1%
ROIVRoivant Sciences Ltd.$-7.1M-2.4%+236.8%
ADAPYAdaptimmune Therapeutics plc$8.3M-1.7%
Torna agli Hedge Fund